Adeno-associated virus vectors for gene therapy: more pros than cons?

被引：169

作者：

Monahan, PE

Samulski, RJ

机构：

[1] Univ N Carolina, Sch Med, Div Hematol Oncol, Chapel Hill, NC 27599 USA

[2] Univ N Carolina, Sch Med, Gene Therapy Ctr, Chapel Hill, NC 27599 USA

[3] Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA

来源：

MOLECULAR MEDICINE TODAY | 2000年 / 6卷 / 11期

关键词：

D O I：

10.1016/S1357-4310(00)01810-4

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Gene therapy vectors based on the adeno-associated virus (AAV) are being developed for a widening variety of therapeutic applications. Enthusiasm for AAV is due, not only to the relative safety of these vectors, but also to advances in understanding of the unique biology of this virus. This review examines a number of long-standing concerns regarding the utility of AAV for gene transfer in light of many new insights into the biology, immunology and production of AAV.

引用

页码：433 / 440

页数：8

共 60 条

[1] Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses
Bantel-Schaal, U
Delius, H
Schmidt, R
zur Hausen, H
[J]. JOURNAL OF VIROLOGY, 1999, 73 (02) : 939 - 947
[2] Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors
Bartlett, JS
Wilcher, R
Samulski, RJ
[J]. JOURNAL OF VIROLOGY, 2000, 74 (06) : 2777 - 2785
[3] Berns Kenneth I., 1996, P1017
[4] Efficient gene transfer into human keratinocytes with recombinant adeno-associated virus vectors
Braun-Falco, M
Doenecke, A
Smola, H
Hallek, M
[J]. GENE THERAPY, 1999, 6 (03) : 432 - 441
[5] Cloning and characterization of adeno-associated virus type 5
Chiorini, JA
Kim, F
Yang, L
Kotin, RM
[J]. JOURNAL OF VIROLOGY, 1999, 73 (02) : 1309 - 1319
[6] Conrad CK, 1996, GENE THER, V3, P658
[7] High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap
Conway, JE
ap Rhys, CMJ
Zolotukhin, I
Zolotukhin, S
Muzyczka, N
Hayward, GS
Byrne, BJ
[J]. GENE THERAPY, 1999, 6 (06) : 986 - 993
[8] SAFETY ASPECTS OF GENE-THERAPY
CORNETTA, K
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 1992, 80 (04) : 421 - 426
[9] Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system
Davidson, BL
Stein, CS
Heth, JA
Martins, I
Kotin, RM
Derksen, TA
Zabner, J
Ghodsi, A
Chiorini, JA
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) : 3428 - 3432
[10] Quantitative analysis of the packaging capacity of recombinant adeno-associated virus
Dong, JY
Fan, PD
Frizzell, RA
[J]. HUMAN GENE THERAPY, 1996, 7 (17) : 2101 - 2112

← 1 2 3 4 5 6 →